Skip Navigation


Annals of Oncology Advance Access originally published online on September 21, 2005
Annals of Oncology 2006 17(3):527-528; doi:10.1093/annonc/mdj014
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/3/527-a    most recent
mdj014v1
Right arrow E-letters: Submit a response
Right arrow E-letters: View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Vincenzi, B.
Right arrow Articles by Tonini, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vincenzi, B.
Right arrow Articles by Tonini, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

letter to the editor

Lack of response of cetuximab plus oxaliplatin in advanced colorectal cancer patients resistant to both oxaliplatin and cetuximab plus irinotecan

The first 10% of the full text of this article appears below.

Colorectal cancer is the third most common cancer in the USA, with ~145 000 new cases expected in 2005 [1Go]. New agents have significantly increased the median overall survival in patients with advanced colorectal cancer and survival times of 21 months have been reported in randomized trials with 5-fluorouracil, irinotecan and oxaliplatin [2Go]; moreover, the promising initial results of targeted therapy will . . . [Full Text of this Article]

B. Vincenzi*, D. Santini and G. Tonini

Medical Oncology, Campus Bio-Medico University, Via Emilio Longoni, 69, 00155 Rome, Italy

* (E-mail: b.vincenzi@unicampus.it)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


E-letters:

Read all E-letters

Reply to ‘Lack of response of cetuximab plus oxaliplatin…’ by B. Vincenzi et al.
Angela J Darby, et al.
Annals of Oncology, 28 Nov 2005 [Full text]